MX2011011109A - Formulaciones orales de bendamustina. - Google Patents
Formulaciones orales de bendamustina.Info
- Publication number
- MX2011011109A MX2011011109A MX2011011109A MX2011011109A MX2011011109A MX 2011011109 A MX2011011109 A MX 2011011109A MX 2011011109 A MX2011011109 A MX 2011011109A MX 2011011109 A MX2011011109 A MX 2011011109A MX 2011011109 A MX2011011109 A MX 2011011109A
- Authority
- MX
- Mexico
- Prior art keywords
- bendamustine
- oral formulations
- methods
- directed
- treatment
- Prior art date
Links
- YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 title abstract 2
- 229960002707 bendamustine Drugs 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17342309P | 2009-04-28 | 2009-04-28 | |
| PCT/US2010/029578 WO2010126676A1 (en) | 2009-04-28 | 2010-04-01 | Oral formulations of bendamustine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2011011109A true MX2011011109A (es) | 2011-11-18 |
Family
ID=42174186
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2011011109A MX2011011109A (es) | 2009-04-28 | 2010-04-01 | Formulaciones orales de bendamustina. |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20120157505A1 (enExample) |
| EP (1) | EP2424506A1 (enExample) |
| JP (1) | JP2012525387A (enExample) |
| CN (1) | CN102413816A (enExample) |
| CA (1) | CA2760085A1 (enExample) |
| MX (1) | MX2011011109A (enExample) |
| WO (1) | WO2010126676A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR072777A1 (es) | 2008-03-26 | 2010-09-22 | Cephalon Inc | Formas solidas de clorhidrato de bendamustina |
| ES2609106T5 (es) | 2010-01-28 | 2020-11-10 | Eagle Pharmaceuticals Inc | Formulaciones de bendamustina |
| JO3659B1 (ar) * | 2010-06-02 | 2020-08-27 | Astellas Deutschland Gmbh | أشكال جرعات بينداموستين عن طريق الفم وإستخداماته العلاجية |
| CN103037851A (zh) * | 2010-06-02 | 2013-04-10 | 安斯泰来德国有限公司 | 苯达莫司汀的口服剂型 |
| CN102125693A (zh) * | 2011-01-25 | 2011-07-20 | 福建科瑞药业有限公司 | 一种盐酸噻加宾药物组合物及其制备方法 |
| CN109157535A (zh) * | 2012-02-14 | 2019-01-08 | 赛多斯有限责任公司 | 苯达莫司汀的制剂 |
| DK3533447T3 (da) | 2012-03-20 | 2023-04-24 | Eagle Pharmaceuticals Inc | Flydende bendamustinsammensætninger til anvendelse i fremgangsmåde til behandling af bendamustin-responsive tilstande hos patienter som kræver reducerede volumener til indgivelse |
| FI2827862T3 (fi) | 2012-03-20 | 2024-02-13 | Eagle Pharmaceuticals Inc | Bendamustiinin formulaatioita |
| EP2641592A1 (en) | 2012-03-23 | 2013-09-25 | Salmon Pharma GmbH | Pharmaceutical formulation comprising bendamustine |
| CN105491886B (zh) | 2013-08-27 | 2019-01-29 | V·沃道里斯 | 苯达莫司汀医药组合物 |
| JP6883428B2 (ja) | 2014-03-13 | 2021-06-09 | ブードーリス，バシリオス | ベンダムスチン固体分散体及び持続注入 |
| CN110772480B (zh) * | 2016-03-25 | 2022-05-17 | 南京百劲企业管理咨询有限公司 | 苯达莫司汀药剂组合物及应用 |
| CA3078290A1 (en) | 2017-10-05 | 2019-04-11 | Tube Pharmaceuticals Gmbh | Oral bendamustine formulations |
| CN110123747A (zh) * | 2019-04-26 | 2019-08-16 | 嘉兴市爵拓科技有限公司 | 苯达莫司汀的制剂 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE159289C (enExample) * | 1903-10-08 | 1905-03-16 | ||
| DD159289A1 (de) * | 1981-06-01 | 1983-03-02 | Uwe Olthoff | Verfahren zur herstellung stabiler injektionsloesungen von n-lostverbindungen |
| DE10306724A1 (de) | 2002-02-28 | 2003-09-18 | G O T Therapeutics Gmbh | Vesikuläre Verkapselung von Bendamustin |
| CN101933923A (zh) * | 2004-11-05 | 2011-01-05 | 赛福伦公司 | 癌症治疗 |
| US8436190B2 (en) * | 2005-01-14 | 2013-05-07 | Cephalon, Inc. | Bendamustine pharmaceutical compositions |
| CN101219113A (zh) * | 2008-01-28 | 2008-07-16 | 济南帅华医药科技有限公司 | 含苯达莫司汀的复方抗癌缓释注射剂 |
-
2010
- 2010-04-01 JP JP2012508503A patent/JP2012525387A/ja active Pending
- 2010-04-01 CN CN2010800183962A patent/CN102413816A/zh active Pending
- 2010-04-01 CA CA2760085A patent/CA2760085A1/en not_active Abandoned
- 2010-04-01 WO PCT/US2010/029578 patent/WO2010126676A1/en not_active Ceased
- 2010-04-01 EP EP10712267A patent/EP2424506A1/en not_active Withdrawn
- 2010-04-01 MX MX2011011109A patent/MX2011011109A/es unknown
-
2011
- 2011-10-28 US US13/284,220 patent/US20120157505A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2424506A1 (en) | 2012-03-07 |
| US20120157505A1 (en) | 2012-06-21 |
| CA2760085A1 (en) | 2010-11-04 |
| JP2012525387A (ja) | 2012-10-22 |
| CN102413816A (zh) | 2012-04-11 |
| WO2010126676A1 (en) | 2010-11-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2011007930A (es) | Conjugados de insulina cristalina. | |
| IL272501A (en) | Oral administration forms of bendamustine and their medical use | |
| MX2011003473A (es) | Composiciones para el cuidado bucal. | |
| MX351464B (es) | El uso de un agonista del receptor 8 tipo toll para el tratamiento de enfermedades alérgicas. | |
| IN2015DN01156A (enExample) | ||
| WO2013072932A3 (en) | Oral care compositions | |
| MY152279A (en) | Immediate release pharmaceutical compositions comprising oxycodone and naloxone | |
| WO2009114118A3 (en) | Oral pharmaceutical compositions of buprenorphine and method of use | |
| MX2013006591A (es) | Formas farmaceuticas orales de liberacion controlada de farmacos escasamente solubles y los usos de estas. | |
| MX2011011950A (es) | Composiciones de dexmedetomidina sublinguales y metodos de uso de las mismas. | |
| MX2013001677A (es) | Formulaciones estables de linaclotida. | |
| MX2014004862A (es) | Formulaciones de polimero acrilico. | |
| MX2019012939A (es) | Formulaciones que contienen linaclotida para administracion oral. | |
| IL216967B (en) | The history of 17-hydroxy-17-pentafluoroethyl-astra-9,4 (10)-diene-11-aryl and their use for the treatment of diseases | |
| PH12012501389A1 (en) | Hedgehog inhibitors | |
| TN2015000135A1 (en) | Modified release formulations for oprozomib | |
| MX2012001691A (es) | Composiciones de linaclotida que se desintegran oralmente. | |
| WO2010121675A3 (en) | Thiazolyl-benzimidazoles | |
| IL225755A0 (en) | Amido-6 derivatives of epoxymorphinans-a5, 4 for the treatment of pain | |
| UA109793C2 (uk) | Арилсульфонаміди для лікування захворювань центральної нервової системи (цнс) | |
| GB201317815D0 (en) | Oral supplementation for the reversal of human hair canities | |
| MX348758B (es) | Derivados de sanglifehrina y metodos para su produccion. | |
| MX2013005825A (es) | Benzoxazepinas como inhibidores de objetivo de rapamicina en mamiferos (mtor) y metodos de uso y fabricacion. | |
| MX2011013324A (es) | Uso de derivados de oxindol sustituidos para el tratamiento y profilaxis del dolor. | |
| MX2015007945A (es) | Usos y métodos para el tratamiento de enfermedades o afecciones hepáticas. |